Contents

Intravitreal Bevacizumab vs. Triamcinolone for Patients with Diabetic Macular Edema at the Time of Cataract Surgery (DIMECAT)

May 1, 2020

Clinical trial

Diabetic retinopathy progression 6 months post-cataract surgery with intravitreous bevacizumab vs triamcinolone: A secondary analysis of the DiMECAT trial.

Sasongko MB, Rogers S, Constantinou M, Sandhu SS, Wickremasinghe SS, Al-Qureshi S, Lim LL.

Clin Exp Ophthalmol. 2020 Aug;48(6):793-801.
Full text | Metrics.

Main finding: Intravitreal bevacizumab and triamcinolone acetonide had decreased progression of diabetic retinopathy compared to previous studies where no adjunctive treatment was administered.

 

 

  • Purpose: To evaluate the progression of diabetic retinopathy in patients treated with intravitreal bevacizumab or triamcinolone at the time cataract surgery
  • Study type: Randomized controlled trial
  • Condition: Cataract surgery in diabetics

Participants: Diabetic patients with fovea-involving diabetic macular oedema plus visually significant cataract

 

  • n=61

 

Intervention:

 

Group 1: Intravitreal bevacizumab 1.25mg
Group 2: Intravitreal triamcinolone 4mg

Intravitreal bevacizumab and triamcinolone acetonide had decreased progression of diabetic retinopathy compared to previous studies where no adjunctive treatment was administered.

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed